London, UK (PRWEB) July 10, 2014
Notwithstanding its considerable patient pool across the US and 5EU acne market has remained stagnant over the past few decades, with no new drugs coming into the arena. The market has seen a shift toward reformulations of existing products and/or fixed-dose combination (FDC) therapies. Examples of the latter comprise combination products offered by the leading dermatology companies, such as Galderma’s Epiduo, Astellas’ Zineryt, and GlaxoSmithKline’s (GSK) Duac.
Studies have shown that it is possible to enhance compliance, and consequently efficiency, by the synergistic combination of two active ingredients. Meantime, new formulations include liposomes, microsponges, aerosol foams, subantimicrobial-dose doxycycline, nanoemulsions and extended-release minocycline. Reformulations are a low-risk strategy for the big pharma industry players, in comparison with placing funds into new molecular substances for acne. Furthermore, during the oncoming decade, other dermatology players are expected to target the previously untapped paediatric market, as acne has become more prevalent in children younger than 12 years old than it once was, potentially owing to the decreasing age of puberty onset.
Across the six major pharma markets, the pharmacological therapy sales for acne are forecast to reach grow from USD 2.3 billion in 2012 to more than USD 2.8 billion by 2018-end, posting a CAGR of around 4%.
In-demand research report “OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018” prepared by GlobalData is now available at MarketPublishers.com.
Title: OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
Published: June, 2014
Price: US$ 5,995.00
The report presents a detailed analysis of the acne prescription therapeutics market in the US and 5EU countries – France, Italy, Germany, Spain, and the UK. It presents an brief overview of acne (epidemiology, pathophysiology, etiology, symptoms and existing treatment modes); features annualised market revenue, cost of therapy per year and treatment usage pattern data (2012-2018); provides a strategic assessment of products; characterises the marketplace; identifies key unmet needs, examines research and development strategies, offers clinical trials information, and gives a benchmarking analysis. An exhaustive pipeline analysis is included, too. Furthermore, the report analyses the market competition (as of now and in the future); as well as sheds light on the key restraints, drivers and challenges in the industry.
Reasons to Buy:
- Overview of acne, including epidemiology, etiology, pathophysiology, symptoms and current treatment options.
- Create strategies (in-and out-licensing) through a thorough review of pipeline products and technologies, and by assessing the companies with the strongest pipeline.
- Benefit from a comprehensive listing of acquisition targets included in the list of early-stage pipeline products.
- Work out business strategies by getting wind of the trends shaping and stimulating the growth in the US and 5EU acne prescription therapeutics sector.
- Drive revenues by benefiting from the valuable information about the major trends, novel technologies and products, market segments, and firms likely to impact market in the years to come.
- Formulate efficient marketing and sales strategies by examining the competition and analysing various competitors’ performance.
- Learn about emerging players with strong product lines and devise effective counter strategies to achieve a competitive edge.
- Keep track of therapy sales in the US and 5EU markets for acne prescription therapeutics during 2012-2018.
- Organise marketing and sales efforts by determining the market categories and segments that offer best opportunities for investments, strategic partnerships and consolidations.
More in-demand research reports by the publisher can be found at GlobalData page.